Status:
COMPLETED
Study of 18F-Fluorodeoxyglucose (FluGlucoScan) in Patients Receiving a Treatment Planning Study of 3 Dimensional Conformal Radiation Therapy Guided by Breath Held CT and PET Imaging for Patients With Non-Small Cell Lung Cancer
Lead Sponsor:
AHS Cancer Control Alberta
Collaborating Sponsors:
Cross Cancer Institute
Conditions:
Lung Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
At this time, computed tomography (CT) is the standard tool used at this institution for the staging of non-small cell lung cancer (NSCLC). For most patients, treatment planning for NSCLC is performed...
Detailed Description
Concurrent chemotherapy and 3-dimensional conformal radiation therapy (3D-CRT), using computed-tomography (CT) simulation, is the current standard approach in the treatment of inoperable non-small-cel...
Eligibility Criteria
Inclusion
- Male or female
- Histologically proven, resected lung cancer of the following histologic types:
- squamous cell carcinoma;
- adenocarcinoma;
- undifferentiated large cell carcinoma;
- non-small cell; and
- not otherwise specified.
- Age equal to or greater than 18 years
- American Joint Committee (AJC) Stage I-III disease (if all detectable tumours can be encompassed by radiation therapy fields, including both the primary tumour and the involved lymph nodes); patients with positive supraclavicular nodes (N3) are not eligible
- Able and willing to follow instructions and comply with the protocol
- Provide written informed consent prior to participation in this study
- Karnofsky Performance Scale score equal to or greater than 70
- Measurable disease on the CT and PET images
- Patient must be deemed eligible for the radical combined-modality therapy.
Exclusion
- Nursing or pregnant females
- MI disease
- N3 disease (patients with positive supraclavicular nodes are not eligible)
- Karnofsky performance status less than 70
- Patients who have undergone complete tumour resection
- Patients with post-resection intrathoracic tumour recurrence
- Evidence of small cell history
- Age less than 18 years
- Prior or concurrent malignancy except non-melanomatous skin cancer (unless disease free for at least 5 years)
- Prior radiotherapy to the thorax or neck
- Prior chemotherapy
- Patients with myocardial infarction within the preceding 6 months or symptomatic heart disease, including angina; congestive heart failure; and uncontrolled arrythmias
- Inability to maintain a state of deep inspiratory breath-hold for a minimum length of time
Key Trial Info
Start Date :
August 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2008
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT00123747
Start Date
August 1 2005
End Date
October 1 2008
Last Update
February 25 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2